| INTRODUCTION
The prevalence of atopic eczema (AE) in children and adolescents has been reported to be as high as 24%, with up to a quarter of patients having moderately severe disease, and 2%-7% being severely affected. 1 Persistence of early-life AE beyond the age of 8 years occurs in 20% of patients, and in 5% for ≥20 years; however in children with severe disease, persistence rates are above 50%. 1 Comorbidities, such as allergic rhinoconjunctivitis and asthma, are common, 2 particularly amongst the more severely affected children, and have additional adverse impact on already impaired quality of life of patients and their families. 3, 4 Healthcare costs associated with AE are high, with an estimated 3 billion dollars being spend per annum in the United States. 1, 4 Topical anti-inflammatory medications and emollients remain the mainstay of treatment, which is increasingly intensive and complex as the severity increases, in particular among patients with comorbidities. 5 Children with persistent severe AE often require systemic immunosuppression and/or systemic corticosteroids, with associated significant long-term side-effects. New emerging monoclonal antibody treatments are promising, 6 but are expensive, and potential long-term risks in children are unclear.
There remains a great need for novel effective treatments, particularly amongst patients at the severe end of the AE spectrum.
Sensitization rates to inhalant allergens among patients with AE are high, 7 and there is evidence that aeroallergen exposure can trigger AE exacerbations. [8] [9] [10] [11] However, studies investigating the use of allergen avoidance and allergen-specific immunotherapy in the treatment of AE have yielded mixed results, and these interventions are currently not recommended in the disease management. 12, 13 A recent meta-analysis of seven studies of house dust mite (HDM) allergen avoidance highlighted the very low-quality evidence currently available, 12 with no studies to date investigating the effect of environmental control among patients with severe AE. We hypothesized that effective reduction in exposure to inhaled allergens and other environmental triggers remains a potentially effective intervention which may reduce disease severity amongst sensitized patients with severe AE. One intervention that has been shown to markedly reduce personal exposure to inhaled allergen, and other inhaled particles are the temperature-controlled laminar airflow (TLA) device. 14, 15 TLA reduces the allergen and particle load in the patients' breathing zone by vertically displacing the contaminations originating from the bed and the room environment 16 and has been shown to be effective in the treatment of atopic asthma. 16, 17 Therefore, to address our hypothesis, we undertook an open-label, proof-of-concept study of the efficacy of a TLA device as an add-on to pharmacological management of children and adolescents with very severe AE.
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| Study design and oversight
This open-label, proof-of-concept study was conducted in a single centre, a tertiary referral Pediatric Allergy Unit at St Mary's Hospital, London, UK. The protocol development, data collection and analyses were completed by investigators. The manufacturer of TLA device (Airsonett AB, € Angelholm, Sweden) provided the devices free of charge, but was not involved in the study design or the interpretation of the results. The protocol was approved by the local research ethics committee. All parents provided written informed consent and children assent. The study is registered as ISRCTN65865773.
| Patients
We enrolled 15 children and adolescents aged 2-16 years with severe AE. AE severity was defined as persistent uncontrolled AE, despite documented high medication requirement. Participants were skin prick tested to HDM, cat, dog, pollen and other allergens if applicable (Stallergenes, Paris, France) and classed as sensitized if the weal diameter was at least 3 mm greater than the negative control.
Only children sensitized to at least one perennial inhalant allergen were recruited. Prior to enrolment, all patients underwent a full multidisciplinary assessment and intensive education programme about the treatment plan (including allergen reduction) for their eczema, and relevant comorbidities (food allergy, asthma/wheeze, allergic rhinoconjunctivitis). During the study, the care of all study participants was provided by one clinician (CG), to minimize variability.
Medication management plan was based upon current best-practice clinical guidelines. What does this article add to our knowledge? Reduction of allergen and particle exposure in the breathing zone using overnight temperaturecontrolled laminar airflow treatment may substantially improve severe atopic eczema.
How does this study impact current management guidelines? Overnight TLA device treatment could be considered as an effective add-on to standard pharmacological management of difficult-to-control atopic eczema. A randomized controlled trial is urgently required.
described in the supplementary appendix. Participants were asked to turn their device on when they went to bed each night, and off in the morning. We assessed adherence by an electronic counter which recorded the total hours of use.
| Study assessments and procedures
Overview of the trial design is shown in Figure 1 . Baseline evaluation included questionnaires on demographics, past medical and family history, sleeping arrangements and pet exposure.
Following the baseline assessment, participants completed a runin period of 6-10 weeks to ensure that their treatment was medically optimized prior to intervention. During the run-in, patients attended three study visits (Baseline Visit, Visits 1 and 2).
Run-in period was followed by a 12-month active treatment period, during which patients attended eight follow-up visits (day 3, 1, 2, 3, 4, 6, 9 and 12 months). AE severity at each visit was documented using the Scoring Atopic Dermatitis (SCORAD) Index 20, 21 and Investigator Global Assessment (IGA, 5-point scale). and Patient-oriented Eczema Measure (POEM). [23] [24] [25] [26] [27] For all participants, outcome assessments were performed by the same physician (CG) at all study visits.
We ascertained cumulative quantities of prescribed medications and numbers of healthcare contacts for AE by obtaining prescription records from the hospital pharmacy, child's primary care physician (general practitioner-GP), and from other specialists, for the period of 12 months before TLA treatment was commenced, and for the 12-month intervention period. One healthcare contact was recorded for each GP prescription for eczema, any other AE-related doctor or specialist nurse contact and for each day spent as a hospital inpatient.
In 12 participants, we determined the effect of TLA device on overnight particulate exposure in patients' breathing zone (Visits 3 and 5). Children slept under the TLA device for two nights, one with the device turned off and one with the device turned on. We continuously sampled the air from the patients' breathing zone (10-12 cm above forehead) for a period of 7 hours, and quantified total airborne particles with aerodynamic equivalent diameter (AED) ≥ 0.5 to ≥10 lm using a laser AEROTRAK 9306 Particle Counter (TSI Inc, Shoreview, MN).
| Efficacy outcomes
The primary efficacy end-point was the change in eczema severity (ascertained by SCORAD Total, and Investigator Global Assessment) during the 12-month intervention period compared to baseline.
Secondary end-points included changes in objective and subjective SCORAD, eczema-related quality of life (patient and family), medication requirements and healthcare utilization (unscheduled healthcare visits).
| Statistical analysis
Detailed description of the statistical analysis is presented in the Supplementary Appendix. Missing data were imputed using the median trajectory. We used nonparametric tests throughout our analyses. We used Friedman test to detect the effect of the treatment and post hoc Wilcoxon signed-rank test to ascertain where the significant differences lie between each pair of observations. All results are presented as medians and interquartile range (IQR). We ascertained change compared to the mid-point run-in visit (Visit 1), unless otherwise indicated. As pilot studies are likely to be underpowered for hypothesis testing at the commonly used significance level of a = .05, and given that we aimed to assess preliminary evidence of the efficacy of TLA treatment, we considered a significance level of a = .1, 28 and corrections for multiple comparisons were not implemented. To provide complete information, P -values adjusted by the Benjamini-Hochberg false discovery rate (FDR) are included in the Supplementary Appendix.
As per recent recommendations for reporting of the pilot trials, 29 in addition to statistical hypothesis testing of changes in end-points described above, we also assessed confidence intervals (CIs) for the treatment effect with respect to the minimum clinically important difference (MCID), which for SCORAD has been shown to be equal to 8.7 [25] . We calculated the mean difference in SCORAD between visit 1 and visit 12, along with a range of CIs (70%-95%). To ascertain whether there was a significant effect of intervention, we F I G U R E 1 Study timeline. BL = Baseline visit, V = Visit, w = weeks, d = days, m = months; Visit 3 and 5 were home visits to ascertain overnight particle exposure in the participants' bedrooms compared the CIs with a "zone of clinical indifference," which we defined as 0 + MCID. 29 
| Exploratory analysis to identify responders to treatment
We used cluster analysis for longitudinal data to identify whether there are subgroups of patients with similar response to TLA treatment. We applied a longitudinal extension of the k-means algorithm (KmL) to SCORAD data, and used the Calinski-Harabasz criterion to determine the optimal number of clusters. 30 Results for post hoc longitudinal cluster analysis were obtained through the KmL package developed in the software environment R. 31 Statistical analyses were carried out using R (http://www.r-projec During the run-in period (median 7.1 weeks, range 6-10 weeks), patients were using maximum topical and additional treatments. The severity of their AE remained high (SCORAD 34.9, IGA 4), and we observed no significant changes in severity and other outcomes between the three run-in visits (except for FDLQI).
3.2 | The effect of TLA on overnight particulate exposures in the breathing zone
We observed a highly significant reduction in airborne particle numbers with TLA treatment across all particle sizes (P < .001, Table E1 ), with a 2600-fold (>99%) reduction in exposure to particles of AED > 5 lm ( Figure S1 ). Figure 2 shows trajectories of primary outcome measures (SCORAD and IGA) from Baseline to Visit 12. There was a highly significant reduction in eczema severity ascertained by both measures during the 12-month intervention period (Friedman test P < .001, Table S2 ).
| Primary end-points
Results of Wilcoxon signed-rank test are presented in Table S3 and show no significant changes in SCORAD and IGA during the run-in period, with a significantly lower AE severity for almost all time-points during the treatment phase compared to the pretreatment values. We observed significant improvements as early as 3 days after commencing intervention ( Figure 2 , Table S3 This suggests that at all CI levels, there is evidence of a potentially clinically important treatment difference. 29 
| Secondary end-points
Trajectories of secondary outcomes from Baseline to Visit 12 are shown in Figure 3 . Through the 12-month intervention period, there was a significant improvement in all secondary severity outcomes, FDQLI and DFI, but not CDQLI (P = .13) and POEM (P = .60) (Table S2 ).
Compared to Visit 1, FDQLI at Visit 12 was significantly lower (16.0 [12.25-19 .0] to 12 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , P = .02), suggesting improvement, as did DFI (P = .01). Figure S3 shows data on medication use and healthcare utilization. We examined the differences at comparable time-points (AE12, AE6, AE3 and AE1 month from the start of intervention). Although graphical inspection of Figure S3 suggests a reduction in these outcomes, the analysis has shown that this was statistically significant only for potent topical corticosteroids (P = .033) and hospital contact for eczema (marginal, P = .081) 6 months after the start of the treatment (Table S4) .
Results of all analyses adjusted for Benjamini-Hochberg False
Discovery Rate are presented in Tables S5-S6 and confirm statistically significant improvements in SCORAD and IGA at 12 months compared to Visit 1 (P = .05 and P = .005, respectively).
| Adherence and acceptability
The TLA device was generally acceptable; 14 of 15 children were content to have the device in situ for the duration of the study, and one participant returned the device after 6 months due to the perceived lack of benefit. Participants used the device for a median of To capture factors which may differentiate the cluster membership, we compared the characteristics between the two groups (Table S8) . A=Asthma, and Cluster A= responders.
F I G U R E 2 Trajectories of the primary outcome measures from Baseline (À10 to À6 wks) to Visit 12 (+12 months). A, Investigator
Global Assessment (IGA). B, SCORAD.
| DISCUSSION
In this proof-of-concept study, the treatment with TLA device in children with very severe AE led to a rapid and significant improvement in eczema severity, which was accompanied by a reduction in medication use, and was sustained over the period of 12 months.
We also observed a significant improvement in some patientreported outcomes and quality of life measures (FDQLI and DFI), but not in CDQLI and POEM. There were no treatment-related adverse effects, and the device was easy to use.
The main limitation of our study is that it is open-label proof-ofconcept, rather than randomized, placebo-controlled trial. As such, our study was not formally powered to assess the effect, but provides evidence to enable a larger definitive trial to be undertaken.
However, the range of effects we describe is of interest. We recruited children with very severe AE from the tertiary referral service, which is a patient group for which there is very little evidence to inform management strategies. During the run-in period, patients attended three visits to ensure optimum treatment and adherence, and achieve as good a control of disease as possible. We cannot exclude the possibility that improved adherence to medications during the treatment period has contributed to some of the improvement which we observed. However, we observed no significant changes in AE severity over the 6-10 weeks of run-in, which makes it unlikely that the later improvements during the intervention phase were due to intensified care, supervision or adherence.
Without a control group, we may have missed spontaneous improvements in AE morbidity. However, this appears unlikely, given the lifelong nature of patients' severe disease, with a median onset of AE at the age of 3 months among subjects in our study. Prior to the inclusion into this study, we observed little changes in AE severity among study participants during a long period of intensive ambulatory multidisciplinary care, which for most patients covered almost entire duration of their disease (median~10 years).
For some outcomes and time-points, the improvement during the intervention period did not reach formal statistical significance.
However, the trends in all outcomes pointed in the same direction that the TLA treatment improved AE control in these severely ill F I G U R E 3 Trajectories of secondary outcome measures from Baseline (À10 to À6 wks) to Visit 12 (+12 mo)
patients. The lack of statistical significance can be explained by the heterogeneity of patients' responses to treatment, which was suggested by our cluster analysis, and a relatively small sample size. We wish to emphasize that given the sample size, and the inclusion of only subjects with a very severe disease, any inference about the potential effectiveness of TLA device is limited to this group of patients.
We do not have data to confirm the mechanisms to explain the observed effects. The purported mode of action of TLA is to reduce the overnight exposure to inhalant allergens during sleep. 14, 16, 17 We have shown in this study that TLA device in patients' homes significantly reduces personal exposure to particles in the size range encompassing all common aeroallergens. [32] [33] [34] The magnitude of the reduction was similar to that seen in the experimental chamber studies, 14 confirming that major reduction in exposure in real life is possible. Allergen challenges in AE patients have shown that exposure to sensitizing allergens via inhaled route induces flares of eczema, [8] [9] [10] [11] and reduction in allergen exposure may be the mechanism behind the effects observed in our study. However, it remains unclear which other factors in the home "exposome" may be relevant for AE severity. For example, there is ample evidence supporting the adverse health effects of air pollution and environmental tobacco smoke (ETS) exposure, and both of these exposures may have a negative impact on AE severity. 35, 36 It should be noted that TLA reduces exposure to all particles in the inhaled air which can be deposited in the respiratory tract. 14, 15 This may reduce personal exposure to a number of pollutants, irritants and other allergens (such as food proteins which are present in house dust 37, 38 ). Thus, potentially important exposures which may be biologically relevant and related to AE severity, and which could be reduced by TLA treatment, include indoor air pollutants, ETS exposure, other allergens such as staphylococcal enterotoxin, [39] [40] [41] other micro-organisms 42 and fungi. 42, 43 It is unclear why a reduction in allergen and/or other inhaled exposures for only a part of the day (6-8 hours during the night) might have a clinical effect. The bed is a place of close contact with a rich allergen reservoir. 43, 44 Convection and flow of warm air transport particle-laden air towards the breathing zone, contributing to potentially higher personal exposure overnight compared with usual daily activities. 45 This process is reversed by the TLA device. 15 Although we do not know enough about the effect of overnight exposures on disease activity, one might hypothesize that allowing a break from exposure to allergens and/or other particles for part of the 24-hour period may allow some recovery, and facilitate immunological changes. Br€ auner et al have shown that reduction of particle exposure using air filtration improved microvascular function. 46 In addition, the contribution of circadian rhythm cannot be excluded. 47 Our cluster analysis suggested that approximately two-thirds of the study participants have responded to the intervention, with no evidence of benefit in the remaining third. Non-responders reported significantly more pruritus and sleep disturbances than responders.
Clinically, it appeared that non-responders had more severely affected hands and feet, but this observation would have to be confirmed in a larger study. Also, much higher use of oral antibiotics among non-responders may indicate that patients with infectioninduced exacerbations of AE may not respond to TLA treatment.
In conclusion, our findings suggest that the addition of TLA device to the standard pharmacological treatment may be an effective add-on to the management of children with difficult-to-treat, severe atopic eczema. We observed improvements in both objective and subjective eczema control measures, which were accompanied by a reduction in medication use. The estimations of the range of possible responses using confidence intervals provided evidence of clinically meaningful differences and support the efficacy of the intervention. Unlike some pharmacological treatments, the use of TLA device is not associated with any side-effects. This is important, as these severely affected patients were already treated with very high doses of currently available topical medications, as well as systemic immunosuppression, and oral corticosteroids. However, our analyses should be considered as predominantly exploratory, providing an indication of preliminary evidence, and should not be used as a tool for verifying or confirming the effectiveness of the intervention. In this context, our study generated a hypothesis, which will require randomized placebo-controlled trials to verify it, both in patients with severe AE and in those with more moderate disease.
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